ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 7.57B 6.66B 6.3B 5.71B 10.73B 727B 10.79B 75.41B 29.12B 371B 28.43B 27.82B 1,192B | P/E 2026 * |
-12.7x | P/E 2027 * | -23.4x |
|---|---|---|---|---|---|
| Enterprise Value | 7.47B 6.57B 6.21B 5.63B 10.58B 717B 10.64B 74.39B 28.73B 366B 28.05B 27.44B 1,176B | EV / Sales 2026 * |
8.12x | EV / Sales 2027 * | 5.6x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 7.4B | |
| +2.64% | +6.45% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +0.40% | +50.91% | +37.06% | 44.5B | |
| -1.58% | +4.66% | +359.34% | +614.38% | 43.93B | |
| +1.70% | +0.36% | +12.56% | +99.27% | 41.03B | |
| +0.51% | -1.71% | +5.18% | +46.87% | 29.85B | |
| -0.48% | -1.32% | +23.98% | +150.01% | 17.27B | |
| +0.08% | +9.03% | +8.41% | - | 15.34B | |
| +1.76% | +0.85% | +29.13% | +48.42% | 15.3B | |
| +1.97% | -3.17% | - | - | 14.82B | |
| Average | +0.82% | +1.63% | +62.67% | +147.77% | 30B | |
| Weighted average by Cap. | +0.76% | +1.89% | +79.47% | +163.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 920M 809M 765M 694M 1.3B 88.27B 1.31B 9.16B 3.54B 45.04B 3.45B 3.38B 145B | 1.36B 1.2B 1.14B 1.03B 1.93B 131B 1.94B 13.59B 5.25B 66.85B 5.12B 5.01B 215B |
| Net income | -576M -507M -479M -435M -816M -55.31B -821M -5.74B -2.22B -28.23B -2.16B -2.12B -90.7B | -330M -290M -275M -249M -468M -31.69B -470M -3.29B -1.27B -16.17B -1.24B -1.21B -51.97B |
| Net Debt | -103M -90.58M -85.65M -77.69M -146M -9.89B -147M -1.03B -396M -5.04B -387M -378M -16.21B | 68.31M 60.08M 56.81M 51.53M 96.77M 6.56B 97.33M 680M 263M 3.35B 256M 251M 10.75B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
